Lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-08. Anything still debated is marked as such rather than presented as settled.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
== Degradation == Ribosomal RNA is quite stable in comparison to other common types of RNA and persists for longer periods of time in a healthy cellular environment. Once assembled into functional units, ribosomal RNA within ribosomes are stable in the stationary phase of the cell life cycle for many hours. Degradation can be triggered via "stalling" of a ribosome, a state that occurs when the ribosome recognizes faulty mRNA or encounters other processing difficulties that causes translation by the ribosome to cease. Once a ribosome stalls, a specialized pathway on the ribosome is initiated to target the entire complex for disassembly.
== Refining the techniques == The next development was gas chromatography (GC). Martin and Synge had predicted its principles in their 1941 paper. Erika Cremer laid the theoretical basis of GC in 1944. Austrian chemist Fritz Prior, under the direction of Erika Cremer, constructed in 1947 the first prototype of a gas chromatograph and achieved separating oxygen and carbon dioxide, in 1947 during his Ph.D. research. Beginning in 1949, Martin and Anthony T. James worked on developing GC. At his 1952 Nobel lecture, Martin announced the successful separation of a wide variety of natural compounds by GC. GC was quickly adopted since it is easy and efficient for separating organic chemicals, and new detection methods for analyzing the output were quickly developed. The thermal conductivity detector, described in 1954 by N. H. Ray, was the foundation for several other methods: the flame ionization detector by J. Harley, W. Nel, and V. Pretorius in 1958, and the electron capture detector by James Lovelock in 1958. Others introduced mass spectrometers to gas chromatography in the late 1950s. The work of Martin and Synge also set the stage for high performance liquid chromatography (HPLC), suggesting that small sorbent particles and pressure could produce fast liquid chromatography techniques. This became widely practical by the late 1960s (and the method was used to separate amino acids as early as 1960).
== Research == Compared to the disease burden of migraine, the amount of healthy life years lost, the field is severely underfunded. In the US in 2019, migraine research got just 7.8% of the funding expected based on its burden. In Europe, it was the most underfunded brain disease when compared to its economic impact.
Those with numerous transport vesicles, which are found primarily in skeletal muscles, fingers, gonads, and skin. Those with few vesicles, which are primarily found in the central nervous system. These capillaries are a constituent of the blood–brain barrier.
Metabolites are the substrates, intermediates and products of metabolism. Within the context of metabolomics, a metabolite is usually defined as any molecule less than 1.5 kDa in size. However, there are exceptions to this depending on the sample and detection method. For example, macromolecules such as lipoproteins and albumin are reliably detected in NMR-based metabolomics studies of blood plasma. In plant-based metabolomics, it is common to refer to "primary" and "secondary" metabolites. A primary metabolite is directly involved in the normal growth, development, and reproduction. A secondary metabolite is not directly involved in those processes, but usually has important ecological function. Examples include antibiotics and pigments. By contrast, in human-based metabolomics, it is more common to describe metabolites as being either endogenous (produced by the host organism) or exogenous. Metabolites of foreign substances such as drugs are termed xenometabolites. The metabolome derives from a large network of metabolic reactions, where outputs from one enzymatic chemical reaction are inputs to other chemical reactions. Such systems have been described as hypercycles.
Sources: en.wikipedia.org
== Honors and awards == In December 2010 he was acknowledged in his individual capacity, as the "Cold Chain Personality of the Year" by an expert panel hosted by KPMG-Supply Chain Leadership Council. The award was in appreciation for individual contributions to the industry and for aligning focus on the socio-economic fabric in India. In 2012 he was applauded with the "Exemplary Thought Leadership Award" by the ICE Centre of Excellence in India. In 2014 he won the prestigious Agribusiness Leadership Award at the annual Agriculture Leadership Summit in New Delhi. In 2016, ISHRAE lauded him as honorary lifetime member, their first ever. He is expert member of the Empowered Committee in the Ministry of New & Renewable Energy for implementation of Montreal Protocol and on the Global Advisory Committee of the International Solar Alliance (ISA) In India, he is recognised as one among the few eminent persons from the private sector who have shifted over to public service by taking on specialist advisory roles in government. His authored documents are frequently cited in the cold chain domain. He is recipient of various recognition and achievement awards from the cold chain industry in India.
== Enthalpy change == The enthalpy of sublimation has commonly been predicted using the equipartition theorem. If the lattice energy is assumed to be approximately half the packing energy, then the following thermodynamic corrections can be applied to predict the enthalpy of sublimation. Assuming a 1 molar ideal gas gives a correction for the thermodynamic environment (pressure and volume) in which pV = RT, hence a correction of 1RT. Additional corrections for the vibrations, rotations and translation then need to be applied. From the equipartition theorem gaseous rotation and translation contribute 1.5RT each to the final state, therefore a +3RT correction. Crystalline vibrations and rotations contribute 3RT each to the initial state, hence −6RT. Summing the RT corrections; −6RT + 3RT + RT = −2RT. This leads to the following approximate sublimation enthalpy. A similar approximation can be found for the entropy term if rigid bodies are assumed.
=== United Kingdom === In 2008, a herd of Wagyu cattle was imported to North Yorkshire, first becoming available for consumption in 2011. Since 2011, there have been Wagyu herds in Scotland. There are British & Irish Wagyu Fullbloods registered through the British Wagyu Breeders Association.
Erythropoietins available for use as therapeutic agents are produced by recombinant DNA technology in cell culture, and include Epogen/Procrit (epoetin alfa) and Aranesp (darbepoetin alfa); they are used in treating anemia resulting from chronic kidney disease, chemotherapy induced anemia in patients with cancer, inflammatory bowel disease (Crohn's disease and ulcerative colitis) and myelodysplasia from the treatment of cancer (chemotherapy and radiation). The package inserts include boxed warnings of increased risk of death, myocardial infarction, stroke, venous thromboembolism, and tumor recurrence, particularly when used to increase the hemoglobin levels to more than 11 g/dL to 12 g/dL.
==== Europe ==== In the Netherlands, diamorphine is a List I drug of the Opium Law. It is available for prescription under tight regulation exclusively to long-term addicts for whom methadone maintenance treatment has failed. It cannot be used to treat severe pain or other illnesses. In the United Kingdom, diamorphine is available by prescription, though it is a restricted Class A drug. According to the 50th edition of the British National Formulary (BNF), diamorphine hydrochloride may be used in the treatment of acute pain, myocardial infarction, acute pulmonary oedema, and chronic pain. The treatment of chronic non-malignant pain must be supervised by a specialist. The BNF notes that all opioid analgesics cause dependence and tolerance but that this is "no deterrent in the control of pain in terminal illness". When used in the palliative care of cancer patients, diamorphine is often injected using a syringe driver. In Switzerland, heroin is produced in injectable or tablet form under the brand name Diaphin by a private company under contract to the Swiss government. Swiss-produced heroin has been imported into Canada with government approval.
Sources: en.wikipedia.org
The program at University of Buenos Aires was similar to a combined BA/MS program in American education. He spent five years learning organic, physical, inorganic, biological and analytical chemistry. This was standard at the time, with the transition to a more focused program occurring during Ondetti's 4th year, making Ondetti one of the last recipients of the generalized degree. The rationale behind the very broad program was that chemists needed to be prepared for all types of industries such as paint, petrochemical or the pharmaceutical industry. At the end of Ondetti's five years, he received a Licentiate in 1955. In the 1950s, Argentina experienced political turmoil and slow economic growth. Many university professors moved to industry jobs, including the head of organic chemistry at the University of Buenos Aires, Dr. Venancio Deulofeu. Ondetti accepted a research training scholarship offered by Squibb following the suggestion from a classmate.
The parathyroid and thyroid glands in the neck produce those hormones; thus, problems with those glands (such as hypo- or hyperparathyroidism or hypo- or hyperthyroidism) can create problems with bone mineral density (as well as hypo- or hypercalcaemia).
==== Agitation of hydrophilic primer or adhesive during application ==== Besides having adequate dentinal moisture, agitation of the primers during application of two-step etch-and-rinse adhesives may be critical for optimal penetration into the demineralized collagen fibres. It also may aid the evaporation of residual water in the adhesive and hybrid layers, thus preventing nano leakage. In a clinical trial comparing the performance of Prime & Bond NT using no rubbing action, slight rubbing action and vigorous rubbing action in the restoration of NCCLs, 92.5% of restorations in vigorous rubbing action group were found to retain after 24 months of clinical service. For the other two groups, the retention rates of the restoration were slightly lower, at 82.5%.
=== 2006–2013: Rise to prominence and subsequent hiatus === Larter auditioned for the science fiction drama television series Heroes on NBC while living in Los Angeles. She played the characters of Niki Sanders, who suffered from dissociative identity disorder, and Tracy Strauss on the show created by Tim Kring. Larter's initial character Niki Sanders, was a wife, mother, and a former internet stripper from Las Vegas exhibiting superhuman strength and alternate personalities who go by the names of Jessica and Niki. "Ali read for the part and just owned it from the second she walked in," Kring said to the Chicago Tribune, "It was a very impressive audition." In the third and fourth seasons, Larter played the new character of Tracy Strauss, who possessed the ability to freeze objects and later, transform her body into water. Larter took on the title role in Marigold (2007), alongside Salman Khan, an Indian actor. The film was released in August 2007 and revolved around Marigold Lexington, an American actress (Larter) who goes to India and gets caught up in the exotic world of Bollywood. Filming took place in North India and London, commencing in June 2004. In an interview with the BBC, Larter remarked this role was "an opportunity to overcome my fear of singing and dancing because I have no professional training... I really focused on the character and loved this journey she went on and the experiences she had." She was paid a seven-figure salary for her part in the film.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.